nach oben

Clinical Rheumatology

Erschienen in:

01.02.2011 | Review Article

Evaluation of current therapeutic strategies in Behçet’s disease

verfasst von: Iliana Alexoudi, Violetta Kapsimali, Aristides Vaiopoulos, Meletios Kanakis, George Vaiopoulos

Erschienen in: Clinical Rheumatology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s disease (BD) is a chronic relapsing vasculitis with multifunctional pathogenesis. The mucocutaneous and ocular lesions are the commonest manifestations, but BD also affects the musculoskeletal, intestinal, cardiac, and central nervous system. BD therapy is based on the suppression of the inflammatory process, using immunomodulating and immunosuppressive agents. In selected cases, invasive procedures may be required.

Alpsoy E, Akman A (2009) Behçet’s disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693–702CrossRefPubMed

Ahmad T, Wallace GR, James T et al (2003) Mapping the HLA association in Behçet’s disease: a role for tumor necrosis factor polymorphisms? Arth Rheum 48:807–813CrossRef

Ceyran H, Akcali Y, Kahraman C (2003) Surgical treatment of vasculo-Behçet’s disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 32:149–153CrossRefPubMed

Kapsimali V, Kanakis M, Vaiopoulos G, et al (2010) Etiopathogenesis of Behçet’s disease with emphasis on the role of immunological aberrations. Clin Rheumatol (in press)

Calamia KT, Kaklamanis PG (2008) Behçet’s disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10:349–355CrossRefPubMed

Gul A (2007) Standard and novel therapeutic approaches to Behçet’s disease. Drugs 67:2013–2022CrossRefPubMed

Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296CrossRefPubMed

Lynde CB, Bruce AS, Rogers RS 3rd (2009) Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 145:273–276CrossRefPubMed

Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 62:827–836PubMed

10.

Kaklamanis P, Kaklamani V (2001) Treatment of Behçet’s disease—an update. Semin Arth Rheum 30:299–312CrossRef

11.

Hatemi G, Silman A, Bang D et al (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528CrossRefPubMed

12.

Seyahi E, Fresko I, Yazici H et al (2006) The management of Behcet syndrome. Acta Rheum Port 31:125–131

13.

Lin P, Liang G (2006) Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 12:282–286CrossRefPubMed

14.

Duygulu F, Evereklioglu MM et al (2005) Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol 24:324–330CrossRefPubMed

15.

Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741CrossRef

16.

Dé Tran QH, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329–335CrossRefPubMed

17.

Bruynzeel I, Van Der Raaij LM, Willemze R, Stoof TJ (1997) Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 289:189–193CrossRefPubMed

18.

Funk JO, Ernst M, Schonharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:1007–1016CrossRefPubMed

19.

Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 134:1010–1016CrossRefPubMed

20.

Nakamura T, Yagi H, Kurachi K, Konno H (2006) Intestinal Behcet’s disease with pyoderma gangrenosum: a case report. World J Gastroenterol 12:979–981PubMed

21.

Fresko I, Yazici H (2008) Treatment strategies for Behçet’s disease. Expert Opin Pharmacother 9:3211–3219CrossRefPubMed

22.

Choi IJ, Kim JS, Cha SD et al (2000) Long-term clinical course and prognostic factors in intestinal Behçet’s disease. Dis Colon Rectum 43:692–700CrossRefPubMed

23.

Lee KS, Kim SJ, Lee BC et al (1997) Surgical treatment of intestinal Behçet’s disease. Yonsei Med J 38:455–460PubMed

24.

Kurata M, Nozue M, Seino K et al (2006) Indications for surgery in intestinal Behçet’s disease. Hepatogastroenterology 53:60–63PubMed

25.

Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258–265CrossRefPubMed

26.

Deuter CM, Kotter I, Wallace GR et al (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136CrossRefPubMed

27.

Kaçmaz RO, Kempen JH, Newcomb C et al (2008) Systemic immunosuppressive therapy for eye diseases cohort study group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836CrossRefPubMed

28.

Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet disease: an open-label trial. Arthritis Rheum 52:2478–2484CrossRefPubMed

29.

Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–285CrossRefPubMed

30.

Akman-Demir G, Ayranci O, Kurtuncu M et al (2008) Cyclosporine for Behçet’s uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(Suppl):S84–S90PubMed

31.

Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903PubMed

32.

Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 50:256–265CrossRefPubMed

33.

Sfikakis PP (2002) Behçet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51–ii53PubMed

34.

Elezoglou A, Kafasi N, Kaklamanis PH et al (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet’s disease. Clin Exp Rheumatol 25(Suppl):S65–S69PubMed

35.

Krause L, Altenburg A, Bechrakis NE et al (2007) Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 245:1617–1621CrossRefPubMed

36.

Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet’s disease. Eur J Ophthalmol 17:191–195PubMed

37.

Sullu Y, Alotaiby H, Beden U, Erkan D (2005) Pars plana vitrectomy for ocular complications of Behçet’s disease. Ophthalmic Surg Lasers Imaging 36:292–297PubMed

38.

Soylu M, Demircan N, Pelit A (2001) Pars plana vitrectomy in ocular Behçet’s disease. Int Ophthalmol 24:219–223CrossRefPubMed

39.

Han JK, Kim HK, Kim YJ et al (2009) Behçet’s disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr 22:1269–1274CrossRefPubMed

40.

Marzban M, Mandegar MH, Karimi A et al (2008) Cardiac and great vessel involvement in “Behcet’s disease”. J Card Surg 23:765–768CrossRefPubMed

41.

Imazio M, Brucato A, Trinchero R et al (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532–539CrossRefPubMed

42.

Arishiro K, Nariyama J, Hoshiga M et al (2006) Vascular Behçet’s disease with coronary artery aneurysm. Intern Med 45:903–907CrossRefPubMed

43.

Ozen S, Bilginer Y, Besbas N et al (2010) Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169:427–430CrossRefPubMed

44.

Oh SH, Lee JH, Shin JU, Bang D (2008) Dermatological features in Behçet disease-associated vena cava obstruction. Br J Dermatol 159:555–560CrossRefPubMed

45.

Alpagut U, Ugurlucan M, Dayioglu E (2007) Major arterial involvement and review of Behçet’s disease. Ann Vasc Surg 21:232–239CrossRefPubMed

46.

Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741–749CrossRefPubMed

47.

Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. J Neurol 256:513–529CrossRefPubMed

48.

Borhani Haghighi A (2009) Treatment of neuro-Behçet’s disease: an update. Expert Rev Neurother 9:565–574CrossRefPubMed

49.

Gono T, Murata M, Kawaguchi Y et al (2009) Successful treatment for sympathetic storms in a patient with neuro-Behçet’s disease. Clin Rheumatol 28:357–359CrossRefPubMed

Titel: Evaluation of current therapeutic strategies in Behçet’s disease
verfasst von: Iliana Alexoudi
Violetta Kapsimali
Aristides Vaiopoulos
Meletios Kanakis
George Vaiopoulos
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 2/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1566-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Spinal mobility and its impact in Moroccan patients with ankylosing spondylitis

Infrapatellar bursitis in children with juvenile idiopathic arthritis: a case series

Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options

Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity

Delays in recognition and management of giant cell arteritis: results from a retrospective audit